It’s European Biotech week, part of global biotech week, do check out #biotechweek on twitter to see what’s going on. Here the UK sector goes from strength to strength. BIA member KalVista opened their new facility as anchor tenants at the Porton Science Park last week. It’s great to see a winner of the Biomedical Catalyst scaling and developing fantastically. With significant new funding via inward investment from the NASDAQ market last month KalVista are developing small molecule plasma kallikrein inhibitors initially targeting hereditary angioedema (HAE) and diabetic macular edema (DME). Congratulations are also due to member Cobra Biologics who were presented with the Queen’s Award 2018 for Enterprise, in the International Trade category on Thursday in recognition of their commercial s
Horizon Discovery Group plc (LSE: HZD) (“Horizon” or “the Company”), a global leader in gene editing and gene modulation technologies, today announced the launch of its Myeloid DNA Reference Standard. The first-to-market large cell-line derived myeloid cancer reference standard designed enables faster, more reliable and more cost-effective assay validation, to support the market in bringing routine testing into practice.
Owlstone Medical Ltd, a global diagnostics company developing a breathalyzer for early disease detection and precision medicine, announced today the addition of Dr Andy Richards CBE to its Board as a Non-Executive Director.
Funding to support Artificial Intelligence (AI) in drug discovery takes a significant step forward today as Optibrium™, Intellegens, and Medicines Discovery Catapult secure a grant from Innovate UK to fund a £1 million project.
The BIA has this week responded to two government consultations that are likely to have significant impacts on the commercial environment for medicines in England.
Over the summer, the Department for Health and Social Care published consultations on proposed changes to the statutory pricing scheme for branded medicines and the introduction of regulations to allow NICE to charge companies for their health technology appraisal programme
CAMBRIDGE, UK, 18 September 2018 – EVONETIX LTD (‘Evonetix’), the company pioneering an innovative approach to scalable and high-fidelity gene synthesis, announced today that it has expanded its team three-fold, following a successful series A round of £9 million ($12.3M) to support the development of the Company’s technology.
A key part of the life sciences industrial strategy, the Novo Nordisk Research Centre opened in Oxford last Wednesday, which is focused on diabetes research. Work there will focus on deepening scientific understanding of diabetes, understanding the impact diabetes has on other health conditions, and analysing patient data to better understand and detect the onset of type II diabetes. The location of the centre will of course allow collaboration with the local ecosystem, tapping into its large talent pool and knowledge base.
Yarvie is an online support system for scientist entrepreneurs working on important health challenges. Our goal is to maximise the probability that early commercialisation projects are a success, by equipping scientists with resources to navigate the process. The system combines highly curated learning from successful projects, and expertise pooled from other scientist entrepreneurs and specialist organisations to guide users through commercial milestones.